Intuitive Surgical's third-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Besides Wall Street's top -and-bottom-line estimates for Intuitive Surgical (ISRG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $490.38, marking a +2% move from the previous day.
ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
In this article, we will take a look into Intuitive Surgical Inc's (ISRG, Financial) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as in the traditional DCF model, the GuruFocus DCF calculator uses EPS without NRI as the default for the DCF model based on research that shows that historically stock prices have been more correlated with earnings than free cash flow.
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $484.76, denoting a -1.33% change from the preceding trading day.
Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $484.39, making no change from the previous trading session.
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Intuitive Surgical remains a leader in robotic surgery despite intensifying competition from Medtronic and Johnson & Johnson. The company's da Vinci procedures grew 17% year-over-year, driving growth in system sales and recurring revenue. Intuitive Surgical reported strong Q2 2024 earnings, with $2.01 billion in revenue, surpassing analysts' estimates.